非小细胞肺癌的疫苗研究

L. Corrales-Rodríguez, N. Blais, D. Soulières
{"title":"非小细胞肺癌的疫苗研究","authors":"L. Corrales-Rodríguez, N. Blais, D. Soulières","doi":"10.4236/WJV.2013.31004","DOIUrl":null,"url":null,"abstract":"Immunotherapy as an option \nof treatment in cancer has experienced an important development with the \ninclusion of vaccines. In lung cancer this type of treatment has emerged and \nvaccines can be classified in three groups: antigen-specific vaccines, tumor cell vaccines, \nand dendritic cell vaccines. Emepepimut (L-BLP25) and MAGE-A3 have been the \nvaccines most widely studied. Their promising results with benefit in survival \nand limited toxicity in preclinical and clinical trials have led to phase III trials with results eagerly \nawaited. Other vaccines have been investigated, but results were not favorable \nor are still pending. Hopefully, vaccines could be an additional instrument for \nthe treatment of lung cancer in the adjuvant or metastatic setting as time will \nunveil the results of current and future trials.","PeriodicalId":57190,"journal":{"name":"疫苗(英文)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2013-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Vaccines in Non-Small Cell Lung Cancer\",\"authors\":\"L. Corrales-Rodríguez, N. Blais, D. Soulières\",\"doi\":\"10.4236/WJV.2013.31004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immunotherapy as an option \\nof treatment in cancer has experienced an important development with the \\ninclusion of vaccines. In lung cancer this type of treatment has emerged and \\nvaccines can be classified in three groups: antigen-specific vaccines, tumor cell vaccines, \\nand dendritic cell vaccines. Emepepimut (L-BLP25) and MAGE-A3 have been the \\nvaccines most widely studied. Their promising results with benefit in survival \\nand limited toxicity in preclinical and clinical trials have led to phase III trials with results eagerly \\nawaited. Other vaccines have been investigated, but results were not favorable \\nor are still pending. Hopefully, vaccines could be an additional instrument for \\nthe treatment of lung cancer in the adjuvant or metastatic setting as time will \\nunveil the results of current and future trials.\",\"PeriodicalId\":57190,\"journal\":{\"name\":\"疫苗(英文)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-02-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"疫苗(英文)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4236/WJV.2013.31004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"疫苗(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4236/WJV.2013.31004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

随着疫苗的加入,免疫疗法作为癌症治疗的一种选择经历了重要的发展。在肺癌中已经出现了这种类型的治疗,疫苗可分为三组:抗原特异性疫苗、肿瘤细胞疫苗和树突状细胞疫苗。empepimut (L-BLP25)和MAGE-A3是研究最广泛的疫苗。它们在临床前和临床试验中有希望的结果,有利于生存和有限的毒性,已经导致了III期试验,结果迫切等待。其他疫苗也进行了研究,但结果并不乐观,或仍在等待结果。随着时间的推移,目前和未来的试验结果将会揭晓,疫苗有望成为辅助或转移性肺癌治疗的额外工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Vaccines in Non-Small Cell Lung Cancer
Immunotherapy as an option of treatment in cancer has experienced an important development with the inclusion of vaccines. In lung cancer this type of treatment has emerged and vaccines can be classified in three groups: antigen-specific vaccines, tumor cell vaccines, and dendritic cell vaccines. Emepepimut (L-BLP25) and MAGE-A3 have been the vaccines most widely studied. Their promising results with benefit in survival and limited toxicity in preclinical and clinical trials have led to phase III trials with results eagerly awaited. Other vaccines have been investigated, but results were not favorable or are still pending. Hopefully, vaccines could be an additional instrument for the treatment of lung cancer in the adjuvant or metastatic setting as time will unveil the results of current and future trials.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
95
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信